Insider buying last 90 days
No open-market insider purchases were filed for ORIC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ORIC insider filing, plotted on the chart in Gekko.Open ORIC in Gekko
NASDAQ: ORIC
Oric Pharmaceuticals (ORIC) Stock Analysis & Forecast
Oct 12 close
$11.81−0.18 (−1.5%)
Gekko Brief
AI summaryOct 12 closeORIC Pharmaceuticals moves this week on a partnership and a flurry of analyst attention. Cancer Research UK has agreed to fully fund and develop ORIC-259, a potential first-in-class CIP2A-targeted therapy, advancing it into clinical development. Alongside this, Leerink Partners initiated coverage on ORIC with an Outperform rating and a $26 price target, part of a broader analyst picture that stands at 9 firms rating the stock buy with a consensus target of $21.43, implying 81.5% consensus upside.
Shares close at $11.81, down 1.5%, sitting between the 50-day average of $13.01 and the 200-day average of $10.95, a mixed trend picture. The GekkoIndex reads 63.2, placing ORIC in the Accumulation zone. Price sits 21.4% below Gekko Fair Value of $15.03, a gap that bears watching. Over one month shares are down 1.9%, while the three-month and six-month returns stand at 11.9% and 13.6% respectively; the 52-week range runs from $7.23 to $14.68.
The next earnings date falls on 12 November 2026, 31 days away, outside a typical 20-trading-day hold; the prior report on 3 August showed an EPS of -0.38 against a -0.36 estimate, with a 21.7% reaction, and 4 beats in the last 8 quarters. Seasonality over 5 years shows the next 20 trading days averaging 0.2%, rising in 3 of those years. Holdings include one billionaire holder and one trailblazer holder, with no insider, Congress, or unusual options activity recorded in their respective windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Oric Pharmaceuticals price vs fair value
Close $11.81200-day averageGekko Fair Value $15.03
Oric Pharmaceuticals quick facts
- Market cap
- $1.22B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.32
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.98
- Volume
- 878,260 avg 1.62M
- 1-year return
- −16.1%
- Typical daily move
- ±6.8%
- Typical 20-day move
- ±16.7%
- 50-day average
- $13.01
- 200-day average
- $10.95
- Next earnings
- Nov 12
- Shares outstanding
- 103.7M
Oric Pharmaceuticals swing-trade checklist
Oric Pharmaceuticals scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $11.81 sits between the 50-day ($13.01) and 200-day ($10.95) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
63.2, Accumulation
Reading 63.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
21.4% below
Price is 21.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.2% on average
From this point in the calendar, the next 20 trading days averaged +0.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Oric Pharmaceuticals stock chart and price history
Oric Pharmaceuticals closed at $11.81 on Oct 12, 2026, −16.1% over the past year, inside a 52-week range of $7.23 to $14.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.9%
- 3 months
- +11.9%
- 6 months
- +13.6%
- 1 year
- −16.1%
The full ORIC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ORIC in Gekko
Follow Oric Pharmaceuticals through every session
Put ORIC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ORIC in GekkoFree for 7 days. No credit card required.
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new cancer therapies for patients in the United States. Its work centers on a pipeline of drug candidates still in clinical testing, including ORIC-533, an oral compound aimed at blocking CD73 to help overcome resistance to chemotherapy and immunotherapy, ORIC-944, which targets a complex linked to prostate cancer growth, and ORIC-114, an orally taken treatment designed to cross into the brain and act against certain EGFR and HER2 mutations tied to tumor growth.
Alongside these programs, the company is working on earlier-stage treatments aimed at other ways cancer cells resist therapy. It has formed outside partnerships to support this work, including a licensing and collaboration arrangement with Voronoi Inc. and a separate licensing agreement with Mirati Therapeutics, Inc.
Oric Pharmaceuticals was founded in 2014 and is headquartered in South San Francisco, California. Its shares are listed on the NASDAQ under the ticker ORIC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- oricpharma.com
Oric Pharmaceuticals GekkoIndex: the smart money zone
Oric Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.2, in the Accumulation zone, up 2.4 points over five sessions.
63.2Accumulation
Up 2.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 60 | −0.1% | +18.8% | ||
| Accumulation (current zone) | 237 | +1.2% | +3.4% | ||
| Neutral | 327 | +0.5% | +0.4% | ||
| Distribution | 51 | +0.9% | +0.3% | ||
| Selling | 7 | Too few readings yet | |||
Average ORIC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ORIC price, zone by zone.Track ORIC in Gekko
Is Oric Pharmaceuticals stock overvalued? Gekko Fair Value
Oric Pharmaceuticals trades 21.4% below Gekko Fair Value of $15.03, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Oric Pharmaceuticals shares are worth, recalculated every trading day.
$15.03
Gekko Fair Value, Oct 10, 2026
21.4% Undervalued
At the end of Aug 2026 the price was 26.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ORIC in Gekko
Oric Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Oric Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ORIC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ORIC, plotted on the chart in Gekko.Open ORIC in Gekko
Buybacks
Oric Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.25M
- As a share of market cap
- 0.10%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold ORIC.
1added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Oric Pharmaceuticals earnings: next date and track record
Oric Pharmaceuticals reports on Nov 12, 2026 (31 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 12, 2026
31 days away
- EPS estimate
- −$0.38
4 of 8reports beat the EPS estimate
±8.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | −$0.38 est −$0.36 | — | +21.7% |
| May 4, 2026 | −$0.34 est −$0.38 | — | −2.0% |
| Feb 23, 2026 | −$0.30 est −$0.37 | — | +20.8% |
| Nov 13, 2025 | −$0.33 est −$0.41 | — | −1.8% |
| Aug 12, 2025 | −$0.47 est −$0.46 | — | +6.8% |
| May 5, 2025 | −$0.42 est −$0.44 | — | −11.1% |
| Feb 18, 2025 | −$0.51 est −$0.51 | $533K | −5.0% |
| Nov 12, 2024 | −$0.49 est −$0.47 | — | −0.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Oric Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Oric Pharmaceuticals is $21.43, +81.5% from the last close, from 9 firms rating the stock in the last 90 days.
$21.43consensus 12-month target, +81.5% from the last close
Now $11.81Avg $21.43
Low $14High $27
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | BTIG | $26 | +120.2% |
| Aug 10 | H.C. Wainwright | $27 | +128.6% |
| Aug 6 | J.P. Morgan | $23 | +94.8% |
| Aug 4 | Evercore ISI | $25 | +111.7% |
| Aug 4 | Stifel Nicolaus | $14 | +18.5% |
+3.4%average 20-day move after past Accumulation readings
+0.2%average move over the next 20 trading days in the last 5 years
±6.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Oric Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Oric Pharmaceuticals averaged +0.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.5% | 2 of 5 |
| Next 10 trading days | −4.5% | 0 of 5 |
| Next 15 trading days | −0.3% | 2 of 5 |
| Next 20 trading days | +0.2% | 3 of 5 |
| Next 30 trading days | +7.3% | 3 of 5 |
For scale, ORIC’s typical 20-trading-day move in either direction is about 16.7%.
Oric Pharmaceuticals market cap and key statistics
Oric Pharmaceuticals’s market cap is $1.22B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.22B
- EPS, TTM
- −$1.32
- Gekko Fair Value
- $15.03
Trading
- Volume
- 878,260
- Avg volume, 20 days
- 1.62M
- 52-week high
- $14.68
- 52-week low
- $7.23
- Shares outstanding
- 103.7M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -39.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.98
- Typical daily move
- ±6.8%
- Typical 20-day move
- ±16.7%
Oric Pharmaceuticals stock news this week
Coverage of Oric Pharmaceuticals this week reads positive: 5 positive, 0 neutral and 0 negative headlines.
- Leerink starts coverage on ORIC Pharmaceuticals stock with USD 26 targetAD HOC NEWS, Oct 7
- ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentYahoo! Finance Canada, Oct 5
- Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated by Analysts at Leerink PartnersMarketBeat, Oct 5
- Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price TargetYahoo Finance, Oct 5
- Oric Pharmaceuticals Inc (ORIC-Q) Stock Price and NewsThe Globe and Mail, Oct 5
Oric Pharmaceuticals peers
Oric Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Oric Pharmaceuticals stock FAQ
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $1.22B at the Oct 12, 2026 close of $11.81, with 103.7M shares outstanding.
What is the Oric Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Oric Pharmaceuticals is $21.43, +81.5% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Oric Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Oric Pharmaceuticals is undervalued: the Oct 12, 2026 close of $11.81 is 21.4% below Gekko Fair Value of $15.03. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Oric Pharmaceuticals report earnings next?
Oric Pharmaceuticals is expected to report on Nov 12, 2026 (31 days away). Analysts expect earnings of −$0.38 per share. Oric Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 8.7% on average across the report.
What is Oric Pharmaceuticals’s 52-week high and low?
Oric Pharmaceuticals’s 52-week high is $14.68 and its 52-week low is $7.23; it closed at $11.81 on Oct 12, 2026, −16.1% over the past year. Over the last five years the shares peaked at $18.58 on Nov 9, 2021.
Is Oric Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Oric Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.